Back to search results
NCT05421663

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Janssen Research & Development, LLC
~166 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-90014496

At a glance

Recruiting sites
0 of 32 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability]
Measured over Up to 15 Years post JNJ-90014496 infusion
+1 more outcome measured

Conditions

Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse

Explore related trials

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaGrade 3b Follicular LymphomaCD19 GeneMS4A1 Gene

NCT05421663

Where you'd take part

This study runs at 32 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Asan Medical Center

    Seoul, South Koreano site contact published

  • Calvary Mater Newcastle Hospital

    Waratah, Australiano site contact published

  • City of Hope

    Duarte, Californiano site contact published

  • Colorado Blood Cancer Institute

    Denver, Coloradono site contact published

  • Erasmus MC

    Rotterdam, Netherlandsno site contact published

  • Fiona Stanley Hospital

    Murdoch, Australiano site contact published

  • Greco Hainesworth Tennessee Oncology Centers for Research

    Nashville, Tennesseeno site contact published

  • Hosp Clinic de Barcelona

    Barcelona, Spainno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Janssen Research & Development, LLC Clinical Trial · STUDY_DIRECTOR · Janssen Research & Development, LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent
Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol
Measurable disease as defined by Lugano 2014 classification
Eastern cooperative oncology group (ECOG) performance status of 0 to 2

Exclusion

History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)
History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis
History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder
Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)
Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection
Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia
Any prior solid organ or allogeneic stem cell transplantation
Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis

What this trial measures

  • Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability]Up to 15 Years post JNJ-90014496 infusion

    Occurrence of any AEs, including dose limiting toxicities (DLTs).

  • Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)Up to 6 months post last participant's JNJ-90014496 infusion

    Overall response is defined as a PR or CR at any point between the time of JNJ-90014496 infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first (per Lugano 2014 guidelines).